Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02578238
Other study ID # P15-619
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 24, 2015
Est. completion date May 31, 2017

Study information

Verified date May 2018
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a non-interventional, observational study of Humira® in the treatment of pediatric CD as per the New Drug Re-examination Guideline in Korea. This study will be conducted in institutions which provide a written agreement to AbbVie Korea, and where the use of Humira® for pediatric CD is following their normal medical practice setting. Pediatric patients who are prescribed Humira® as per physician's medical judgment in accordance with the approved Korean local label will be enrolled in the study. As this is a post marketing surveillance, AbbVie is NOT involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.


Recruitment information / eligibility

Status Completed
Enrollment 143
Est. completion date May 31, 2017
Est. primary completion date May 31, 2017
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria:

- Pediatric patients with CD who are prescribed Humira in accordance with the Korean label for Humira authorization (labeling)

- Patients who have given written authorization to use their personal health data for the purposes of this study.

Exclusion Criteria:

- Any contraindications to Humira as listed on the approved product market authorization (labeling)

- Patients who is participating on other clinical trials.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs/ADRs and Unexpected AEs/ADRs An AE is defined as any untoward medical occurrence, which does not necessarily have a causal relationship with their treatment. If an AE meets any of the following criteria, it is considered a serious AE: results in death, is life-threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, is an important medical event requiring medical or surgical intervention to prevent serious outcome. An ADR label was used for an AE when causal relationship with a pharmaceutical drug could not be excluded. From Day 0 (informed consent) to up to 70 days following the last administration of Humira®. The mean length of treatment was 52.81 (±45.58) weeks (calculated based on participants with available start date data [n=142]).
See also
  Status Clinical Trial Phase
Completed NCT02772965 - Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy Phase 3
Completed NCT02869880 - Trial of Enhanced Pre-Consent Discussion N/A
Completed NCT01580670 - Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease Phase 3
Withdrawn NCT01752790 - Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease Phase 4
Terminated NCT02694042 - Mission is Remission®: How Can a Disease Self-management Website Change Care? N/A

External Links